Skip to main content

Mylan launches generic Gleevec


HERTFORDSHIRE, England, and PITTSBURGH — Mylan is expanding its offering of oncology generics with its latest introduction. The company has launched its generic of Gleeven (imatinib mesylate) tablets.

The drug is approved to treat multiple indications, including several blood cancers, the company said. The drug had U.S. sales of approximately $1.7 billion for the 12 months ended July 31, according to QunitilesIMS data. The product will be available in 100- and 400-mg dosage strengths.

This ad will auto-close in 10 seconds